Aim: The recently developed direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infections are costly. Cost-effectiveness analyses of DAAs require accurate healthcare expenditure estimates for the various HCV disease states, but few studies have produced such estimates using national-level data. This study utilized nationally representative data to estimate the healthcare expenditure for each HCV disease state.
Methods: We identified all patients infected with HCV between April 2010 and March 2018 from a nationwide administrative claims database in Japan. Monthly patient-level healthcare expenditures were calculated for the following disease states: chronic hepatitis C (CHC), compensated cirrhosis (CC), decompensated cirrhosis (DC), and hepatocellular carcinoma (HCC). The expenditures for the CHC and CC states were also compared before DAA treatment and after sustained virologic response (SVR) was achieved. A longitudinal two-part model was employed to estimate the healthcare expenditures for each state.
Results: During the study period, 1,564,043 patients with 146,488,137 patient-months of data met the inclusion criteria. The year of valuation was 2017. The mean monthly healthcare expenditures per patient (95% confidence intervals) for the pre-DAA CHC, CC, DC, and HCC states were US$267 (US$267-268), US$428 (US$427-429), US$666 (US$663-669), and US$969 (US$966-972), respectively. The mean monthly healthcare expenditures per patient for the post-SVR (≥ 2 years) CHC and CC states were US$176 (US$176-177) and US$238 (US$236-240), respectively. Healthcare expenditure increased with increasing age in all disease states (P < 0.05).
Conclusions: These healthcare expenditure estimates from a nationally representative sample have potential applications in cost-effectiveness analyses of DAAs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40273-019-00861-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacy Subscription Program and Medication Refills, Days' Supply, and Out-of-Pocket Costs.
JAMA Netw Open
January 2025
Amazon Health Services, Seattle, Washington.
Importance: Medication nonadherence imposes high morbidity, mortality, and costs but is challenging to address given its multiple causes. Subscription models are increasingly used in health care to encourage healthy behaviors; in January 2023, Amazon Pharmacy launched RxPass, a subscription program offering Amazon Prime members (hereafter, company members) in 45 states access to 60 common generic medications for a flat $5 monthly fee.
Objective: To evaluate the associations of program enrollment with medication refills, days' supply, and out-of-pocket costs.
Spatial association of socioeconomic and health service factors with antibiotic self-medication in Thailand.
Geospat Health
January 2025
Faculty of Public Health, Khon Kaen University, Khon Kaen.
Antibiotic Self-Medication (ASM) is a major contributing factor to Antimicrobial Resistance (AMR) that can lead to both mortality and long-term hospitalizations. High provincial ASM proportions associated with mortality due to AMR have been observed in Thailand but there is a lack of studies on geographic factors contributing to ASM. The present study aimed to quantify the distribution of ASM in Thailand and its correlated factors.
View Article and Find Full Text PDFExploring the role of the JEEViKA swasthya mitra helpdesk in improving healthcare access: a qualitative study in tertiary healthcare facilities in Bihar, India.
BMC Health Serv Res
January 2025
Bihar Rural Livelihoods Promotion Society (BRLPS) "JEEVIKA", Patna Bihar, India.
Background: Rural populations in Bihar, India, face significant healthcare access challenges due to geographical, infrastructural, and financial barriers. The Swasthya Mitra program, initiated by the Bihar Rural Livelihood Promotion Society in collaboration with local and international partners, aims to mitigate these challenges by employing trained community members to navigate patients through the healthcare system.
Methods: This qualitative study employed in-depth interview and thematic analysis to evaluate the Swasthya Mitra program in the Bhagalpur and Jamui districts in Bihar, India.
Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes.
BMC Cardiovasc Disord
January 2025
MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 80 Bond Street, Toronto, ON, M5B 1X2, Canada.
Background: Since national essential medicine lists guide the procurement of medicines for populations in many countries, and cardiovascular diseases are the leading cause of death globally, including cardiovascular medicines on these lists can significantly impact healthcare outcomes.
Methods: In this cross-sectional study, national essential medicines' lists from 158 countries were analysed on whether or not they included medicines to treat ischemic heart disease, cerebrovascular disease, and hypertensive heart disease. A linear regression model was used to evaluate the association between countries' coverage scores and amenable mortality.
Safety, tolerability and therapeutic efficacy of anti-inflammatory drug pirfenidone in acute pancreatitis patients: Protocol for a randomized pilot clinical trial.
Pancreatology
January 2025
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA; Veterans Affairs Medical Center, Birmingham, AL, USA. Electronic address:
Background: Acute Pancreatitis (AP) is a formidable disease with significant morbidity, mortality and healthcare expenditure. There is an emergent need to develop therapeutic agents for this disease as there are no targeted therapies available. We have recently demonstrated that pirfenidone can significantly decrease the severity of AP in animal models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!